Know Cancer

forgot password

Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [F] F.G.-PET Scanning

Phase 2
18 Years
70 Years
Open (Enrolling)

Thank you

Trial Information

Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [F] F.G.-PET Scanning



- Determine the 2-year progression-free survival (PFS) rate after treatment with
rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in patients with bulky stage
II or stage III or IV diffuse large B-cell non-Hodgkin's lymphoma who remain positron
emission tomography (PET)-positive after 3 courses of rituximab, cyclophosphamide,
vincristine, doxorubicin hydrochloride, and prednisone.


- Determine the proportion of mid-treatment PET-positive patients who become PET-negative
after 4 courses of R-ICE.

- Determine the PFS of mid-treatment PET-negative patients treated with these regimens.

- Determine the overall survival of patients treated with these regimens.

- Determine the toxicity of these regimens in these patients.


- Rituximab and CHOP chemotherapy (R-CHOP): Patients receive rituximab IV,
cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and
oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 4 courses
in the absence of disease progression or unacceptable toxicity. Patients undergo
fludeoxyglucose F18 positron emission tomography (PET) scanning and conventional
restaging during course 3. Based on the PET results, patients are assigned to 1 of 2
treatment groups.

- Group I (PET negative): Patients receive 2 more courses of R-CHOP as above in the
absence of disease progression or unacceptable toxicity.

- Group II (PET positive): Patients receive R-ICE comprising rituximab IV on day 1,
ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day
2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim
(G-CSF) subcutaneously once daily starting on day 4 and continuing until blood
counts recover. Treatment repeats every 14 days for 4 courses in the absence of
disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 10 years from
the date of study entry.

PROJECTED ACCRUAL: A total of 99 patients will be accrued for this study.

Inclusion Criteria


- Diffuse large B-cell non-Hodgkin's lymphoma

- Bulky stage II (bulk defined as any lesion ≥ 10 cm) or stage III or IV disease

- The following lymphoma types are excluded:

- Primary central nervous system lymphoma

- Transformed low-grade lymphoma (prior history of low-grade lymphoma or
clear presence of low-grade lymphoma on histologic sections)

- Primary mediastinal B-cell lymphoma or testicular lymphoma (consolidative
radiotherapy is usually indicated)

- Immunodeficiency-related lymphoma (i.e., after organ or bone marrow

- Measurable disease

- Patient must have at least one objective measurable disease site (i.e.,
measurable in at least 2 perpendicular parameters)

- Measurable disease in the liver is required if the liver is the only site of
lymphoma involvement

- Abnormal positron emission tomography scans will not constitute evaluable
disease, unless verified by CT scan or other appropriate imaging


- ECOG performance status 0-3

- For patients > 50 years of age, a normal ejection fraction by ECHO or MUGA is
required within 6 weeks prior to registration

- Absolute neutrophil count ≥ 1,500/mm^3*

- Platelet count > 100,000/mm^3*

- Creatinine < 2.0 mg/dL*

- Bilirubin < 2 mg/dL (may be up to 3.0 mg/dL if due to liver involvement by lymphoma)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use an accepted and effective method of contraception

- No prior malignancy within the past 5 years unless it was in situ OR was treated with
curative intent AND the patient has remained relapse-free

- HIV negative NOTE: *Unless abnormal due to lymphoma


- No prior chemotherapy or radiation therapy for lymphoma

- No prior anthracyclines or platinum compounds used as systemic chemotherapy

- No prior radiation therapy to the mediastinum or to ≥ 25% of the bone marrow

- No concurrent pentostatin or trastuzumab (Herceptin®)

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

2- year progression-free survival (PFS)

Outcome Time Frame:

Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years.

Safety Issue:


Principal Investigator

Lode J. Swinnen, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Sidney Kimmel Comprehensive Cancer Center


United States: Federal Government

Study ID:




Start Date:

April 2006

Completion Date:

Related Keywords:

  • Lymphoma
  • contiguous stage II adult diffuse large cell lymphoma
  • noncontiguous stage II adult diffuse large cell lymphoma
  • stage III adult diffuse large cell lymphoma
  • stage IV adult diffuse large cell lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell



Mayo Clinic - Jacksonville Jacksonville, Florida  32224
Mayo Clinic Cancer Center Rochester, Minnesota  55905
Hurley Medical Center Flint, Michigan  48503
CCOP - Illinois Oncology Research Association Peoria, Illinois  61602
CCOP - Carle Cancer Center Urbana, Illinois  61801
CCOP - Iowa Oncology Research Association Des Moines, Iowa  50309-1016
Rush-Copley Cancer Care Center Aurora, Illinois  60507
Evanston Northwestern Healthcare - Evanston Hospital Evanston, Illinois  60201-1781
Hinsdale Hematology Oncology Associates Hinsdale, Illinois  60521
Joliet Oncology-Hematology Associates, Limited - West Joliet, Illinois  60435
Carle Cancer Center at Carle Foundation Hospital Urbana, Illinois  61801
Saint Anthony Memorial Health Centers Michigan City, Indiana  46360
Mercy Medical Center - Sioux City Sioux City, Iowa  51104
Siouxland Hematology-Oncology Associates, LLP Sioux City, Iowa  51101
St. Luke's Regional Medical Center Sioux City, Iowa  51104
CCOP - Michigan Cancer Research Consortium Ann Arbor, Michigan  48106
Saint Joseph Mercy Cancer Center Ann Arbor, Michigan  48106-0995
Oakwood Cancer Center at Oakwood Hospital and Medical Center Dearborn, Michigan  48123-2500
Genesys Hurley Cancer Institute Flint, Michigan  48503
Van Elslander Cancer Center at St. John Hospital and Medical Center Grosse Pointe Woods, Michigan  48236
Bronson Methodist Hospital Kalamazoo, Michigan  49007
West Michigan Cancer Center Kalamazoo, Michigan  49007-3731
Borgess Medical Center Kalamazooaa, Michigan  49001
Sparrow Regional Cancer Center Lansing, Michigan  48912-1811
St. John Macomb Hospital Warren, Michigan  48093
Duluth Clinic Cancer Center - Duluth Duluth, Minnesota  55805-1983
CCOP - Duluth Duluth, Minnesota  55805
Miller - Dwan Medical Center Duluth, Minnesota  55805
Aultman Cancer Center at Aultman Hospital Canton, Ohio  44710-1799
MetroHealth Cancer Care Center at MetroHealth Medical Center Cleveland, Ohio  44109
Penn State Cancer Institute at Milton S. Hershey Medical Center Hershey, Pennsylvania  17033-0850
Geisinger Medical Group - Scenery Park State College, Pennsylvania  16801
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center Wilkes-Barre, Pennsylvania  18711
Sanford Cancer Center at Sanford USD Medical Center Sioux Falls, South Dakota  57117-5039
Medical X-Ray Center, PC Sioux Falls, South Dakota  57105
Avera Cancer Institute Sioux Falls, South Dakota  57105
Dean Medical Center - Madison Madison, Wisconsin  53717
Marshfield Clinic - Marshfield Center Marshfield, Wisconsin  54449
Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin  53226
Froedtert Hospital and Medical College of Wisconsin Milwaukee, Wisconsin  53226-3596
Marshfield Clinic - Indianhead Center Rice Lake, Wisconsin  54868
Methodist Medical Center of Illinois Peoria, Illinois  61636
Newark Beth Israel Medical Center Newark, New Jersey  07112
Hinsdale, Illinois  60521
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland  21231-2410
Veterans Affairs Medical Center - Palo Alto Palo Alto, California  94304
John Stoddard Cancer Center at Iowa Methodist Medical Center Des Moines, Iowa  50309
SUNY Downstate Medical Center Brooklyn, New York  11203
NYU Cancer Institute at New York University Medical Center New York, New York  10016
Lewistown Hospital Lewistown, Pennsylvania  17044
Mount Nittany Medical Center State College, Pennsylvania  16803
Baptist Cancer Institute - Jacksonville Jacksonville, Florida  32207
Geisinger Cancer Institute at Geisinger Health Danville, Pennsylvania  17822-0001
Gundersen Lutheran Center for Cancer and Blood La Crosse, Wisconsin  54601
Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois  60611
Front Range Cancer Specialists Fort Collins, Colorado  80528
St. Joseph Medical Center Bloomington, Illinois  61701
Graham Hospital Canton, Illinois  61520
Memorial Hospital Carthage, Illinois  62321
Eureka Community Hospital Eureka, Illinois  61530
Galesburg Cottage Hospital Galesburg, Illinois  61401
Mason District Hospital Havana, Illinois  62644
Hopedale Medical Complex Hopedale, Illinois  61747
McDonough District Hospital Macomb, Illinois  61455
BroMenn Regional Medical Center Normal, Illinois  61761
Community Cancer Center Normal, Illinois  61761
Community Hospital of Ottawa Ottawa, Illinois  61350
Oncology Hematology Associates of Central Illinois, PC - Ottawa Ottawa, Illinois  61350
Cancer Treatment Center at Pekin Hospital Pekin, Illinois  61554
Oncology Hematology Associates of Central Illinois, PC - Peoria Peoria, Illinois  61615
OSF St. Francis Medical Center Peoria, Illinois  61637
Proctor Hospital Peoria, Illinois  61614
Illinois Valley Community Hospital Peru, Illinois  61354
Perry Memorial Hospital Princeton, Illinois  61356
St. Margaret's Hospital Spring Valley, Illinois  61362
Bettendorf, Iowa  52722
John Stoddard Cancer Center at Iowa Lutheran Hospital Des Moines, Iowa  50316-2301
Mercy Capitol Hospital Des Moines, Iowa  50307
Medical Oncology and Hematology Associates at John Stoddard Cancer Center Des Moines, Iowa  50309
Medical Oncology and Hematology Associates at Mercy Cancer Center Des Moines, Iowa  50314
Mercy Cancer Center at Mercy Medical Center - Des Moines Des Moines, Iowa  50314
Bryn Mawr Hospital Bryn Mawr, Pennsylvania  19010
Lankenau Cancer Center at Lankenau Hospital Wynnewood, Pennsylvania  19096
McFarland Clinic, PC Ames, Iowa  50010
Greater Baltimore Medical Center Cancer Center Baltimore, Maryland  21204
Foote Memorial Hospital Jackson, Michigan  49201
St. Mary Mercy Hospital Livonia, Michigan  48154
St. Joseph Mercy Oakland Pontiac, Michigan  48341-2985
Mercy Regional Cancer Center at Mercy Hospital Port Huron, Michigan  48060
Seton Cancer Institute at Saint Mary's - Saginaw Saginaw, Michigan  48601
Christ Hospital Cancer Center Cincinnati, Ohio  45219
Center for Cancer Treatment & Prevention at Sacred Heart Hospital Eau Claire, Wisconsin  54701
Marshfield Clinic Cancer Care at Regional Cancer Center Eau Claire, Wisconsin  54701
Saint Joseph's Hospital Marshfield, Wisconsin  54449
Marshfield Clinic - Lakeland Center Minocqua, Wisconsin  54548
Ministry Medical Group at Saint Mary's Hospital Rhinelander, Wisconsin  54501
Saint Michael's Hospital Cancer Center Stevens Point, Wisconsin  54481
Marshfield Clinic - Wausau Center Wausau, Wisconsin  54401
Marshfield Clinic - Weston Center Weston, Wisconsin  54476
Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids, Wisconsin  54494
Galesburg Clinic, PC Galesburg, Illinois  61401
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus Moline, Illinois  61265
Cancer Center of Paoli Memorial Hospital Paoli, Pennsylvania  19301-1792
CCOP - Main Line Health Wynnewood, Pennsylvania  19096